Stratification
pulmonary and non-pulmonary co-morbidities, cancer, asthma, non-respiratory comorbidities, COPD, diabetes
UNCONTROLLED HYPERTENSION, BRONCHIECTASIS, HEART DISEASE, CANCER, COPD, ASTHMA, DIABETES
As the benefits of COVID-19 treatments may be different depending on prior co-morbidities, study participants were stratified as follows: no relevant prior illness; pre-existing lung conditions (ILD, COPD, bronchiectasis, asthma); and other relevant non-respiratory comorbidities (e.g. diabetes, heart disease, uncontrolled hypertension, cancer). Participants with both pulmonary and non-pulmonary co-morbidities were included in the pulmonary stratum.Generalised linear models (GLMs) with a binomial response and canonical link were used to analyse the primary endpoint. The predictor variables used were stratum, sex and treatment. As no interim analyses were conducted, p-values quoted are two-sided rather than one-sided. For more details of statistical analyses, please see the supplemental appendix. Other baseline and outcome variables were reported using summary statistics appropriate for either categorical or continuous variables, as needed.